http://epaper.dailymirror.lk/epaper/viewer.aspx
India has purchased 500 million doses of the Oxford University-AstraZeneca vaccine candidate, one billion from the US company Novavax and 100 million doses of the Sputnik V candidate from Russia's Gamaleya Research Institute, according to the US-based Duke University Global Health Innovation Center.
https://indianexpress.com/article/india/india-biggest-buyer-of-covid-19-vaccine-with-1-6-billion-doses-experts-say-this-could-cover-60-population-7092076/
India too has not opted for the vaccine produced by Pfizer/BioNtech owing to the ultra cold - chain requirements.
India is also developing its own vaccine which has reached phase 3 trial stage.